Pheochromocytoma Clinical Trials 2023

Pheochromocytoma Clinical Trials 2023

Pheochromocytoma research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in pheochromocytoma clinical trials today.

Trials for PCC Patients

Trials for Paraganglioma Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to pheochromocytoma

What are the top hospitals conducting pheochromocytoma research?

In the realm of clinical trials for pheochromocytoma, several prominent hospitals are working tirelessly to advance our understanding and treatment options for this rare adrenal gland tumor. At the National Institutes of Health Clinical Center in Bethesda, groundbreaking research is underway with four active trials focused on pheochromocytoma. Over the years, they have contributed to a total of seven such trials since recording their first endeavor in 2000. Meanwhile, Memorial Sloan Kettering Cancer Center in New york has joined the mission by currently conducting three active pheochromocytoma trials. Although their overall count may seem modest at three all-time trials since 2006, each study represents an important step forward.

M D Anderson Cancer Center leads from Houston as another powerhouse dedicated to battling this challenging condition. With three ongoing pheochromocytoma studies and a cumulative tally of seven completed trials since embarking on their inaugural investigation in 2011, they continue to make significant strides towards improving patient outcomes. Not far behind is the University of Iowa located in Iowa City, where two current pheochromocytoma clinical trials are making notable contributions alongside their previous three conducted studies dating back to 2009.

It's worth noting that M D Anderson Cancer Center's second location also plays an integral role within this field; together with its main campus it shares two ongoing pheochromocytoma investigations while having carried out a combined total of three over time starting from around twelve years ago(around same time).

These remarkable institutions across various locations exemplify the unwavering commitment that medical professionals have towards finding better solutions for patients affected by rare conditions like pheochromocytoma. Every trial conducted brings us closer to unlocking new treatments and ultimately offers hope for those facing these daunting health challenges

Which are the best cities for pheochromocytoma clinical trials?

When it comes to pheochromocytoma clinical trials, several cities stand out as hubs for research and innovation. New york City leads the pack with 12 active trials investigating treatments such as Tipifarnib, Axitinib, and Lanreotide. Los Angeles follows closely behind with 10 ongoing studies focused on Nivolumab, Tipifarnib, and Doxazosin. Anchorage in Alaska also shows promise with 9 active trials exploring options like Nivolumab and Tipifarnib. Additionally, Houston in Texas has 7 active trials studying Lutetium [177Lu] oxodotreotide/dotatate, EO2401, Belzutifan among others. Lastly, Bethesda in Maryland contributes to the field with 6 ongoing trials investigating ([18F]-6F-DA), Talazoparib, Temozolomide along with other potential breakthroughs. These cities offer individuals affected by pheochromocytoma access to cutting-edge clinical trials that pave the way for advancements in care and bring hope for better treatment outcomes.

Which are the top treatments for pheochromocytoma being explored in clinical trials?

Exciting developments are underway in the realm of pheochromocytoma treatment, with several promising options being explored in clinical trials. One highly anticipated contender is Lutetium [177Lu] oxodotreotide/dotatate, currently involved in one active trial and representing a breakthrough since its first listing in 2022. Another potential game-changer is EO2401, also undergoing investigation in one ongoing trial after making its debut on the scene in 2020. Rounding out this trio of top contenders is Axitinib, showcasing its potential through one active trial following its introduction to the field back in 2019. As researchers delve into these treatments further, hope continues to grow for improved outcomes and enhanced quality of life for individuals battling pheochromocytoma.

What are the most recent clinical trials for pheochromocytoma?

Exciting advancements in clinical trials offer hope for individuals with pheochromocytoma, a rare neuroendocrine tumor. Among the most recent studies is a trial investigating dose escalation as a potential treatment strategy. This trial encompasses both Phase 1 and Phase 2, showcasing its comprehensive approach to evaluating safety and efficacy. Another notable study explores the use of Lutetium [177Lu] oxodotreotide/dotatate for pheochromocytoma patients, aiming to harness targeted therapy to combat this challenging condition. Furthermore, Talazoparib presents promise as an innovative treatment option through its involvement in a Phase 2 trial. These studies highlight the ongoing commitment towards finding effective treatments and improving outcomes for those affected by pheochromocytoma

What pheochromocytoma clinical trials were recently completed?

Mayo Clinic recently completed a notable clinical trial in May 2017 investigating the efficacy of Lenvatinib for pheochromocytoma. This trial marks an important step in advancing our understanding and treatment options for this rare neuroendocrine tumor.